Novo Nordisk (NVO) plans to launch its blockbuster weight-loss drug Wegovy in vial format. The move targets customers who have shifted to rival Eli Lilly & Co. (LLY).
Strategic Shift in Packaging
This packaging change follows Eli Lilly’s lead in offering similar options for obesity treatments. Novo Nordisk currently distributes Wegovy exclusively through plastic injector pens.
The update aims to broaden accessibility and boost competitiveness in the growing market for weight management drugs.
